Thursday, June 19, 2025

Aurobindo Pharma commissions four plants in Andhra Pradesh including Pen-G facility

Date:

Hyderabad: Aurobindo Pharma on Monday said it has commissioned four state-of-the-art manufacturing facilities for Penicillin-G, 6-Amino Penicillanic Acid (6-APA), Injectable products and Granulation, through its wholly owned subsidiaries.

Penicillin-G (Pen-G) facility, located in a SEZ at Kakinada in Andhra Pradesh, has a production capacity of 15,000 tonne per annum and also 1.8 lakh tonne of glucose, while 6-Amino Penicillanic Acid plant can produce 3,600 tonne annually, the drug maker said in a press release.

The Rs 2,400 crore Pen-G plant is expected to start trial production in April and commercial production in a couple of months and the ramping up of the production will happen during the second quarter of the current fiscal, a senior official of the city-based drug maker had earlier said.

The plant was approved under the Production Linked Incentive (PLI) Scheme for the Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country.

The injectable plant can produce 285 million of Vials/Ampoules annually and the Granulated products plant will produce 13,200 tonnes annually, Aurobindo said.

PTI

Related articles

The Dark Side of Bill Gates’ Philanthropy: Bill Gates Urges Government to Implement Mandates for Digital India and Control on AI

The Dark Side of Bill Gates' Philanthropy in Digital India Are Bill Gates and his foundation truly working for...

Did 5G and Cloud Seeding Combine for Disaster in Uttarakhand? Exploring Aviation Safety Risks

The recent tragic helicopter crash in Uttarakhand has sparked a wave of speculation and concern, with many focusing...

Discovering the Dark Side of Aviation:  Inside Story of Boeing Whistleblowers and the Tragedy of Air India Flight 787-8 Dreamliner

The Air India Boeing 787-8 Dreamliner crashed shortly after takeoff in Ahmedabad on Thursday, killing 241 of 242...

Bioweapon-COVID Variants: Discover how Bill Gates invests in a lab to explore the possibility of developing more ‘transmissive and fatal’ variants

Qvive focused on bringing to light what is often not talked about. Learn about the joint efforts of the...